Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Jürgen Eckhardt - aVenture Research

Jürgen Eckhardt

AddedMar 31, 2024

UpdatedOct 13, 2026

Jürgen Eckhardt

Jürgen Eckhardt

Board Member, AMR Action Fund

Jürgen Eckhardt's Career

AMR Action Fund

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Board Member· Board

Immunitas Therapeutics

Series B$97MWaltham, MA, US

Board Member· Board

Oerth Bio

Series D$55MDurham, NC, US

Board Member· Board

Vesigen Therapeutics

Series A$28.5MCambridge, MA, US

Board Member· Board

Khloris Biosciences

Series A$5MSouth San Francisco, CA, US

Board Member· Board

Triumvira Immunologics

Series A$100MAustin, TX, US

Board Member· Board

Joyn Bio

Series A$200MBoston, MA, US

Board Member· Board

Metagenomi

Public$457MEmeryville, CA, US

Board Member· Board

Dewpoint Therapeutics

Series C$287MBoston, MA, US

Board Member· Board

eGenesis

Series D$456MCambridge, MA, US

Board Member· Board

Bayer

Public$3.7BLeverkusen, North Rhine-Westphalia, DE

Managing Director

People Similar to Jürgen Eckhardt

Elliott SigalBoard Member · Amgen Ventures

Marijn DekkersFounder · Novalis LifeSciences

Andy SchwabBoard Member · National Venture Capital Association

Kristina BurowBoard Member · AgTech Accelerator

Fred HassanBoard Member · Amgen Ventures

Julie SunderlandManaging Director · Biomatics Capital Partners

Leadership at AMR Action Fund

Henry B. SkinnerCEO

Aleks EngelBoard Member

Bill BurnsBoard Member

Similar to AMR Action Fund

Special Situations Life Sciences Innovation FundSpecial Situations Life Sciences Innovation Fund

Fund makes seed and early-stage investments in companies focused

Leadership at Immunitas Therapeutics

Geeta VemuriBoard Member

Laura BrassBoard Member

K. Dane WittrupBoard Member

Mario SuvaCo-Founder

Brian HalakBoard Member

Amanda WagnerCEO

Similar to Immunitas Therapeutics

Immune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35

Leadership at Oerth Bio

John DombroskyCEO

Similar to Oerth Bio

76BioNew York City, NY, USProtein Degradersest. 202076BioNew York City, NY, US · est. 2020

76Bio, a NY-based biotech firm, pioneers targeted protein degraders for life-threatening diseases.

Series A · $10M16

ArvinasNew Haven, CT, USTherapeuticsest. 2013ArvinasNew Haven, CT, US · est. 2013

US-based Arvinas, Inc. develops protein degradation therapeutics for cancer and other diseases globally.

Public · $461.6M415

TerMirRaleigh, NC, USAgricultural Productsest. 2016TerMirRaleigh, NC, US · est. 2016

TerMir: A biotech AgTech firm providing innovative solutions for agronomic and environmental challenges.

BiotheryxSan Diego, CA, USBiopharmaceuticalsest. 2007BiotheryxSan Diego, CA, US · est. 2007

US-based BioTheryX: Developing therapies for hematological malignancies.

Public · $134.7M39

Leadership at Vesigen Therapeutics

Paulash MohsenCEO

Stephen BrusoBoard Member

Robert MillmanCo-Founder

Quan LuCo-Founder

Gerald ChanBoard Member

Similar to Vesigen Therapeutics

Strm.BioCambridge, MA, USGene Therapyest. 2019Strm.BioCambridge, MA, US · est. 2019

STRM.BIO: Pioneering efficient, safe, and scalable gene therapy via extracellular vesicles.

Leadership at Khloris Biosciences

Joseph C. WuCo-Founder

Lynne A. BuiCo-Founder

Similar to Khloris Biosciences

Shinobi TherapeuticsSouth San Francisco, CA, USCell Therapiesest. 2023Shinobi TherapeuticsSouth San Francisco, CA, US · est. 2023

Shinobi Therapeutics, a California-based biotech firm, innovates immune-evasive cell treatments.

Series A · $51M30

I PeacePalo Alto, CA, USStem Cellsest. 2015I PeacePalo Alto, CA, US · est. 2015

I Peace, Inc.: A leading provider of iPSC technology, safeguarding health for a happier life.

Series A · $22.9M18

International Stem CellCarlsbad, CA, USBiotech Productsest. 2005International Stem CellCarlsbad, CA, US · est. 2005

Oceanside-based International Stem Cell Corp. develops therapeutic biotech products for treating various diseases.

Public · $7.5M29

Altos LabsRedwood City, CA, USCell Therapiesest. 2021Altos LabsRedwood City, CA, US · est. 2021

Altos Labs, Inc.: An American biotech firm pioneering life extension therapies via specialized cell therapies since 2022.

Series A · $3B500

Leadership at Triumvira Immunologics

Cynthia CollinsBoard Member

Brian BloomBoard Member

Elizabeth WilliamsBoard Member

Widya MulyasasmitaBoard Member

Connor McDermottBoard Member

Paul LammersCEO

Similar to Triumvira Immunologics

Trio PharmaceuticalsSan Diego, CA, USCancer Therapeuticsest. 2018Trio PharmaceuticalsSan Diego, CA, US · est. 2018

Innovative cancer therapeutics company developing affordable, dual-action treatments for enhanced efficacy and reduced toxicity.

Seed · $3.7M30

Leadership at Joyn Bio

Reshma ShettyBoard Member

Jason KellyBoard Member

Michael MiilleCEO

Similar to Joyn Bio

Switch BioworksSan Carlos, CA, USFertilizerest. 2022Switch BioworksSan Carlos, CA, US · est. 2022

Switch Bioworks: Engineering symbiotic microbes for sustainable, precision-controlled nitrogen fertilizer production.

Pre-Seed · $8.1M11

Pivot BioBerkeley, CA, USAgricultural Productsest. 2010Pivot BioBerkeley, CA, US · est. 2010

Pivot Bio, Inc.: A US-based AgriTech firm innovating plant nutrition by harnessing atmospheric nitrogen.

Series D · $616.9M488

GrowcentiaFort Collins, CO, USMicrobial Probioticsest. 2015GrowcentiaFort Collins, CO, US · est. 2015

Growcentia: Enhancing crop yields and nutrient efficiency with advanced microbial probiotics.

Series A · $5M40

Kula BioSomerville, MA, USOrganic Fertilizerest. 2018Kula BioSomerville, MA, US · est. 2018

Kula Bio: Pioneering sustainable, organic fertilizers through energized microbes for modern agriculture.

Series A · $72.1M14

Leadership at Metagenomi

Risa StackBoard Member

Jillian BanfieldCo-Founder

Brian ThomasCEO

Willard DereBoard Member

Santhosh PalaniBoard Member

Similar to Metagenomi

Emendo BiotherapeuticsNew York City, NY, USGene Editingest. 2015Emendo BiotherapeuticsNew York City, NY, US · est. 2015

Emendo Biotherapeutics: Advancing gene therapy with next-gen gene-editing tools for genetic disorders.

Acrigen Biosciences

Leadership at Dewpoint Therapeutics

Richard YoungCo-Founder

Giuseppe CiaramellaBoard Member

Ameet NathwaniCEO

Mark MurckoBoard Member

Amir NashatBoard Member

Olivier BrandicourtBoard Member

Similar to Dewpoint Therapeutics

Faze MedicinesCambridge, MA, USTherapeuticsest. 2020Faze MedicinesCambridge, MA, US · est. 2020

Faze Medicines: A pioneering biotech company specializing in biomolecular condensate therapeutics.

Series A · $81M40

Recent news

eGenesis Announces Clinical Update in Ongoing Expanded Access Study of EGEN-2784 in Patients with Kidney FailureeGenesis · 2026

eGenesis Appoints Glenn S. Vraniak as Chief Financial Officer and Jennifer Bergheiser as Chief Commercial OfficereGenesis · 2026

eGenesis Announces IND Clearance for EGEN-2784 in Kidney Transplant and Landmark Patient Updates in Ongoing Expanded Access StudyeGenesis · 2025

Leadership at eGenesis

Bob MoreBoard Member

Al WiegmanBoard Member

Similar to eGenesis

Qihan Biotechest. 2017Qihan Biotechest. 2017

Qihan Biotech develops genome-edited cells and xenogeneic organs for therapy.

Series B · $117M

Makana Therapeuticsest. 2009Makana Therapeuticsest. 2009

Leadership at Bayer

Norbert BischofbergerBoard Member

Paul AchleitnerBoard Member

Wolfgang NicklBoard Member

Bill AndersonBoard Member

Rodrigo SantosBoard Member

Stefan OelrichBoard Member

Similar to Bayer

AbCellera BiologicsVancouver, British Columbia, CAAntibody Discoveryest. 2012AbCellera BiologicsVancouver, British Columbia, CA · est. 2012

Vancouver-based AbCellera Biologics researches and develops human antibodies using proprietary technology.

Public · $889M495

ImmunaiNew York City, NY, USBiomarkers, Biotechest. 2018ImmunaiNew York City, NY, US · est. 2018

Immunai, a biotech firm, uses single-cell genomics and ML for high-resolution immune profiling and biomarker discovery.

Series B · $295M167

ImmunoGenesisHouston, TX, USCancer Therapiesest. 2019ImmunoGenesisHouston, TX, US · est. 2019

ImmunoGenesis: Developing science-based therapies to combat immune-resistant tumors.

Public · $28M38

INmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17

Carmine TherapeuticsCambridge, MA, USGene Therapiesest. 2019

Carmine TherapeuticsCambridge, MA, US · est. 2019

Carmine Therapeutics: Pioneering non-viral gene therapies via red blood cell vesicles.

Series A · $3.4M39

Arrakis TherapeuticsWaltham, MA, USMedicines, Therapeuticsest. 2015Arrakis TherapeuticsWaltham, MA, US · est. 2015

Waltham-based biotech firm specializing in innovative solutions for global health challenges.

Series B · $113M121

Sivec BiotechnologiesFort Collins, CO, USDrug Delivery, Vaccinesest. 2016Sivec BiotechnologiesFort Collins, CO, US · est. 2016

SiVEC Biotechnologies: Pioneering non-pathogenic bacteria for targeted drug and vaccine delivery.

Tactiva TherapeuticsBuffalo, NY, USCancer Treatmentest. 2016

Tactiva TherapeuticsBuffalo, NY, US · est. 2016

Tactiva Therapeutics: Specializing in potent dual T cell receptor cancer immunotherapy.

Series A · $35M30

3T BiosciencesSouth San Francisco, CA, USImmunotherapy, Therapeuticsest. 20173T BiosciencesSouth San Francisco, CA, US · est. 2017

3T Biosciences, founded in 2017, is a California-based immunotherapy company.

Series A · $52M33

Tizona TherapeuticsSouth San Francisco, CA, USCancer Treatment, Immunotherapyest. 2015Tizona TherapeuticsSouth San Francisco, CA, US · est. 2015

Tizona Therapeutics develops advanced immunology-based treatments for cancer and autoimmune diseases.

Late Stage Private · $370M46

Alameda, CA, US

Gene Editingest. 2019

Acrigen BiosciencesAlameda, CA, US · est. 2019

Acrigen Biosciences: Precision gene-editing tech firm developing therapies for genetic disorders.

Seed · $1.2M11

Editas MedicineCambridge, MA, USGene Editing, Therapiesest. 2013Editas MedicineCambridge, MA, US · est. 2013

Editas Medicine, Inc.: A clinical-stage biotech firm pioneering CRISPR-based therapies for rare diseases.

Public · $931.6M226

Arbor BiotechnologiesCambridge, MA, USGene Editingest. 2016Arbor BiotechnologiesCambridge, MA, US · est. 2016

Arbor Biotechnologies: Pioneering biodiscovery with AI, genome sequencing, and high-throughput screening.

Series B · $230.6M170

Transition BioCambridge, MA, USDrug Discoveryest. 2020

Transition BioCambridge, MA, US · est. 2020

Transition Bio: Pioneering biomolecular condensate analysis tech for precise drug discovery.

Series A · $50M50

Nereid TherapeuticsBoston, MA, USDrug Discoveryest. 2020Nereid TherapeuticsBoston, MA, US · est. 2020

Nereid Therapeutics: Innovating drug discovery with proprietary technologies for new disease treatments.

Series A · $50M12

Triana BiomedicinesWaltham, MA, USBiopharmaceuticalsest. 2019Triana BiomedicinesWaltham, MA, US · est. 2019

Triana Biomedicines: A biopharmaceutical pioneer, innovating disease-targeting molecular glue technology.

Series A · $160.8M37

Boris NikolicBoard Member

Daniel LynchBoard Member

Luhan YangBoard Member

Makana Therapeutics develops gene-edited pig kidneys for kidney failure.

United TherapeuticsSilver Spring, MD, USPharmaceuticalsest. 1996United TherapeuticsSilver Spring, MD, US · est. 1996

United Therapeutics, a Maryland-based biotech firm, develops pharmaceuticals for vascular diseases using synthetic prostacyclin.

TransMedicsAndover, MA, USMedical Devicesest. 1998TransMedicsAndover, MA, US · est. 1998

TransMedics, a Massachusetts-based manufacturer, offers tech and clinical solutions for heart and lung transplants.

Public · $721.3M212

Exeltisest. 2003

Exeltisest. 2003

Pharmaceutical group developing treatments across women's and men's health.

4k

Libbs FarmaceuticaSão Paulo, BRPharmaceuticalsest. 1958Libbs FarmaceuticaSão Paulo, BR · est. 1958

Libbs, a Brazil-based pharmaceutical company, committed to health, producing innovative solutions since 1958.

Key Pharmaceuticalsest. 1985Key Pharmaceuticalsest. 1985

Australian consumer healthcare company marketing over-the-counter medicines, devices, dermocosmetics and personal care products.

51-200 employees